The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Frontline quadruplet therapy for multiple myeloma: Update from SOHO 2024
|
Quadruplet therapies combining anti-CD38 monoclonal antibodies, a proteasome inhibitor, an immunomodulatory agent, and dexamethasone in sequence with ASCT lead to deep and durable responses in NDMM.1 A review of outcomes in patients treated with upfront quadruplet therapies was presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting by Ajay Nooka.1
|
| Key learnings: |
|
The phase III PERSEUS (NCT03710603) trial demonstrated deep and durable responses with daratumumab + VRd compared with VRd in patients with transplant-eligible NDMM. |
|
Real-world findings and long-term results from the CASSIOPEIA trials confirmed the benefit of daratumumab-based quadruplet therapies in NDMM. |
|
Isatuximab + VRd demonstrated improved post-induction MRD negativity compared with VRd in the GMMG-HG7 (NCT03617731) trial. |
|
The phase III IMROZ (NCT03319667) and BENEFIT (NCT04751877) trials demonstrated that quadruplet therapies can improve the depth of response and lead to high rates of MRD negativity. This translated into a 63% 5-year PFS benefit for isatuximab + VRd vs VRd in the IMROZ study. |
|
Benefits of upfront quadruplet therapies in high-risk disease were demonstrated in the MASTER (NCT03224507) and GMMG-CONCEPT (NCT03104842) trials, and for transplant-ineligible elderly patients in the ALCYONE trial (NCT02195479). |
|
These findings suggest upfront quadruplet therapies as the preferred SoC for transplant-eligible and transplant-ineligible patients. The depth of response and high PFS rates offer the potential for improved disease control, delaying relapse. |
ASCT, autologous stem cell transplantation; MRD, measurable residual disease; NDMM, newly diagnosed multiple myeloma; PFS, progression-free survival; SoC, standard of care; VRd, bortezomib + lenalidomide + dexamethasone.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
